CTOs on the Move

Zavante Therapeutics

www.zavante.com

 
Zavante is a clinical-stage biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients.
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.zavante.com
  • 12670 High Bluff Dr
    San Diego, CA USA 92130
  • Phone: 858.705.2365

Executives

Name Title Contact Details

Funding

Zavante Therapeutics raised $35M on 03/29/2016

Similar Companies

TopoTarget USA

TopoTarget USA is a Rockaway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ColoWrap

ColoWrap is the first clinical colonoscopy compression device that prevents the need for manual abdominal pressure and patient repositioning during colonoscopy.

Rainier Therapeutics

Rainier is a uniquely diverse manufacturing company, producing a variety of display, shelter, fabric and shading products. Our mission is to create the highest quality available in everything we create--using the best technology and materials. Rainier consistently meets demanding requirements--and we`re at our best creating new solutions.

Trilogy Behavioral Healthcare

Trilogys Mission is to support people in their recovery from mental illness by helping them discover and reclaim their capabilities and well being.

Opko

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.